UID:
(DE-602)almahu_9949850865602882
Format:
1 online resource (348 pages)
Edition:
First edition.
ISBN:
0-323-90242-1
,
0-323-90243-X
Series Statement:
Handbook of clinical neurology ; Volume 202
Note:
Intro -- Hematopoietic Stem Cell Transplantation for Neurologic Diseases -- Copyright -- Handbook of Clinical Neurology 3rd Series -- Dedication -- Foreword -- Preface -- Contributors -- Contents -- Chapter 1: Introduction to HSCT for neurologic diseases -- Introduction -- References -- Chapter 2: Modification of T- and B-cell-associated immuno-pathologic mechanisms in multiple sclerosis by disease modifyi ... -- Background -- Body Compartments-The Outside -- Early development toward naive lymphocytes -- Lymphocyte activation in secondary lymphoid organs -- Secondary lymphoid organ egress and migration -- Body Compartments-The Inside -- The perivascular unit -- Meningeal infiltrates -- Parenchymal white matter lesions -- The Future of MS Disease-Modifying Therapies -- References -- Chapter 3: The hematopoietic niche and the autoreactive memory in autoimmune disorders -- The Hematopoietic Niche -- Major Components of the Hematopoietic Niches -- Inflammatory Adaptation -- From Immune Cell Progenitors to Autoreactive Memory -- Conclusions and Future Directions -- Acknowledgments -- References -- Chapter 4: The preclinical data and immunologic rationale for hematopoietic stem cell transplantation in autoimmunity -- Immunologic Tolerance and Autoimmunity1 -- The role of the thymus in ADs -- Positive and negative selection of T cells in the thymus -- Experimental Models of ADs and Methods of HSCT/BMT Treatment -- The Role of Bone Marrow and Hematopoietic Stem Cells in ADs -- Allogeneic HSCT in Animal Models of ADs -- Autologous and Syngeneic BMT in AD Models (Table 4.1) -- The Question of T-cell Depletion of the BM Graft and the Optimal Conditioning for HSCT/BMT -- Discussion -- References -- Chapter 5: Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis -- Introduction.
,
Bone Marrow Transplantation in Experimental Models of Autoimmune Diseases -- Bone Marrow Recovery: Definition and Kinetics of Immune Cell Repopulation -- Mechanisms of Immune Cell Recovery -- Reconstitution and Renewal of the Immune System Following AHSCT in MS -- T cells -- Phenotypic analyses: Early expansion of memory T cells and late increase of naïve T cells -- De novo generation of naïve T cells in a reactivated thymus -- Renovation of the T cell repertoire -- Reactivity to myelin antigens and depletion of proinflammatory phenotypes -- Proinflammatory T helper cells (Th1 and Th17) -- Restoration of a T regulatory network -- B cells -- NK cells -- Cytokine and chemokine networks -- Immune gene expression and posttranscriptional modulation -- Immunologic Markers of Response to AHSCT -- Memory stem cells: Perspective study in HSCT -- Immune System Reconstitution and Prolonged Disease Activity Suppression: Conclusive Insights Into the Potential Mechanism of A -- Acknowledgment -- References -- Chapter 6: Immune reconstitution in rheumatic disease patients after autologous hematopoietic stem cell transplantation -- Introduction1 -- Autoimmune and autoinflammatory diseases -- Causes of autoimmunity: Genetic, epigenetic, and environmental factors -- Rationale of auto-HSCT for autoimmune diseases -- Influence of genetic and immunologic factors on the outcome of autologous HSCT for autoimmune diseases -- Autologous Hematopoietic Stem Cell Transplantation -- Mobilization of hematopoietic stem cells from the bone marrow -- Conditioning regimens -- Basic Mechanisms of Immune Reconstitution in Rheumatic Diseases -- Reconstitution of T cells -- Early phases of T cell reconstitution -- Thymic reactivation and naïve T cell output -- T cell receptor (TCR) repertoire diversity -- Recovery of regulatory T cells -- Recovery of T lymphocyte subsets.
,
Reconstitution of B cells -- Reconstitution of innate immune cells -- Specific Topics -- Secondary autoimmune diseases -- Posttransplant immunosuppression -- Macrophage activation syndrome after auto-HSCT -- Conclusions -- References -- Chapter 7: The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablat ... -- Introduction1 -- Mobilization -- Conditioning Regimen -- Conditioning regimens: Classification -- A ``historical perspective´´ on conditioning regimen use in MS -- Conditioning regimens in other autoimmune neurologic diseases -- Evolving trends in selection of the intensity -- Intensities Face to Face: Is There Evidence of Superior Benefit? -- Conclusions -- References -- Chapter 8: The HSCT procedure (I): Mobilization, collection, manipulation, and cryopreservation of a HSC graft -- Introduction -- Hematopoiesis and Hematopoietic Stem Cell Biology -- Sources of HSC -- Methods of Collection -- Bone marrow harvest -- Peripheral blood stem cell -- Umbilical cord blood -- Graft Quality Assessment -- Graft Engineering -- Cryopreservation, Storage, and Thawing -- Regulation -- Stem Cell Collection in Autoimmune Diseases -- Conclusions -- References -- Chapter 9: The HSCT procedure (II): Conditioning, hematopoietic stem cell infusion, supportive care, and monitoring -- Introduction -- Conditioning -- Serotherapies -- Cyclophosphamide regimens -- BEAM regimen -- Cytarabine -- Etoposide -- Melphalan -- Hematopoietic Stem Cell Infusion -- Central venous catheter -- Stem cell thawing and infusion -- Premedication and adverse events management -- Supportive Care -- Nutritional support -- Transfusion support -- Infection prophylaxis -- Environmental control -- Antimicrobial prophylaxis -- Monitoring -- Graft function -- Infections and immune function -- Ocular and oral monitoring.
,
Respiratory monitoring -- Cardiovascular monitoring -- Liver and renal monitoring -- Endocrine monitoring -- Secondary tumors monitoring -- References -- Further reading -- Chapter 10: Early and late complications of hematopoietic stem cell transplantation -- Noninfectious Complications of ASCT -- Acute toxicity -- Long-term complications -- Early and Late Infectious Complications of ASCT -- Introduction -- Rate of infectious complications -- Febrile neutropenia and bacterial infections -- Viral infections -- Fungal infections -- Vaccination after ASCT for SM -- Reproductive Issues in Multiple Sclerosis Patients Scheduled for ASCT -- Evaluation of gonadal function and fertility after gonadotoxic treatments -- Definition and assessment of ovarian reserve -- Gonadal function and fertility in MS patients after ASCT -- Fertility preservation techniques -- References -- Chapter 11: Hematopoietic stem cell transplantation for multiple sclerosis -- Multiple Sclerosis, Treatment Goals, and Unmet Needs -- AHSCT in MS Patients -- The procedure -- Fertility preservation -- Previous DMT exposure -- AHSCT procedure -- Neurologic monitoring after AHSCT -- Evidence of Efficacy -- Randomized controlled studies -- Long-term outcomes -- Retrospective controlled studies -- Disability improvement -- AHSCT and MRI measures of brain damage -- AHSCT and cerebrospinal fluid findings -- AHSCT and novel biomarkers of demyelination and axonal damage -- The role of the conditioning regimen -- Safety -- Transplant-related-mortality -- Malignancies -- Secondary autoimmune disorders -- Patient Selection and Recommendations -- Progressive MS -- Conclusions and Future Perspectives -- References -- Chapter 12: Hematopoietic stem cell transplantation for neuromyelitis optica spectrum disorder. Can immune tolerance be r ... -- History of Neuromyelitis Optica Spectrum Disorder (NMOSD)1.
,
Demographics -- NMOSD and MOGAD antibodies (Table 12.1) -- Criteria for NMOSD (Table 12.2) -- Differential diagnosis of demyelinating diseases (Table 12.3) -- Cerebrovascular disease -- Inherited diseases -- Vasculitides -- Migraines -- Connective tissue diseases -- CNS infections -- Inherited mitochondrial disease -- Leukodystrophy -- Autoimmune -- NMOSD demographics -- NMOSD standard treatment -- Randomized trials (Table 12.5) -- Autologous hematopoietic stem cell transplantation (HSCT) for NMOSD (Table 12.6) -- Autologous HSCT case series -- Autologous HSCT retrospective study -- Autologous HSCT prospective study -- Allogeneic HSCT for NMOSD -- Does HSCT reestablish immune tolerance? -- Conclusions -- References -- Chapter 13: Hematopoietic stem cell transplantation (HSCT) for chronic inflammatory demyelinating polyradiculoneuropathy ... -- Is the Diagnosis of CIDP Correct?1 -- Electrophysiology (EPS) -- EPS terminology -- Motor NCS -- Sensory NCS -- Interpretation of NCS -- Acquired Peripheral Neuropathies (Table 13.2) -- Peripheral neuropathy arising from systemic autoimmune diseases -- Inherited Peripheral Neuropathies -- HNPP -- CMT (Table 13.3 -- Fig. 13.3) -- Demyelinating CMTs (CMT1, CMT4) -- Axonal CMTs (CMT2, CMT5, CMT6) -- CMTs that may be either demyelinating or axonal CMT (CMTX, DI-CMT, CMT3) -- Summary of CMT -- General Dysimmune Neuropathies -- Antimyelin-associated glycoprotein (anti-MAG) neuropathy -- Multifocal motor neuropathy (MMN) -- CANOMAD -- GBS and variants -- Nodopathies/paranodopathies (Table 13.6 -- Fig. 13.4) -- Chronic Inflammatory Demyelinating Polyradiculoneuropathy -- Demographics -- Typical vs Atypical CIDP (Table 13.7) -- Criteria for CIDP -- EFNS/PNS clinical criteria for CIDP (Table 13.8) -- EFNS/PNS supportive/exclusion criteria for CIDP (Table 13.8) -- EFNS/PNS electrophysiology criteria for CIDP (Table 13.9).
,
EFNS/PNS diagnosis of CIDP (Table 13.10).
Language:
English
Bookmarklink
